Do we Still Need Human Embryonic Stem Cells for Stem Cell-Based Therapies? Epistemic and Ethical Aspects

Hug, Kristina; Hermerén, Göran

doi:10.1007/s12015-011-9257-3

Cited by 23 publications

(11 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The success of stem cell therapy may largely depend on high‐efficient supply of desired functional cell types . However, the limited supply of required stem cells, low‐efficient conversion technologies, unstable genetic manipulation, and complex ethical controversies are the main challenges in the field . In addition, the risks of stem cell‐based interventions include immunological reactions, tumor formation, and unknown long‐term health effects .…”

Section: Introductionmentioning

confidence: 99%

Myt1l induced direct reprogramming of pericytes into cholinergic neurons

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Myt1l induced direct reprogramming of pericytes into cholinergic neurons

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The recent breakthrough in producing ES-like cells (induced pluripotent stem, iPS, cells) by reprogramming differentiated cells with transcription factors alone or in combination with small molecules was a much welcomed alternative to ES cells, as the use of iPS cells would circumvent ethical issues [12][13][14]. However, the fact that iPS cells, like ES cells, are tumorigenic [7,9], have low induction efficiency and seem to maintain an epigenetic memory of the cell type of origin, can hinder their use in clinical applications.…”

Section: Embryonic Stem Cells and Induced Pluripotent Stem Cellsmentioning

confidence: 99%

Autologous stem cells for personalised medicine

Prasongchean¹,

Ferretti²

2012

New Biotechnology

View full text Add to dashboard Cite

Increasing understanding of stem cell biology, the ability to reprogramme differentiated cells to a pluripotent state and evidence of multipotency in certain adult somatic stem cells has opened the door to exciting therapeutic advances as well as a great deal of regulatory and ethical issues. Benefits will come from the possibility of modelling human diseases and develop individualised therapies, and from their use in transplantation and bioengineering. The use of autologous stem cells is highly desirable, as it avoids the problem of tissue rejection, and also reduces ethical and regulatory issues. Identification of the most appropriate cell sources for different potential applications, development of appropriate clinical grade methodologies and large scale well controlled clinical trials will be essential to assess safety and value of cell based therapies, which have been generating much hope, but are by and large not yet close to becoming standard clinical practice. We briefly discuss stem cells in the context of tissue repair and regenerative medicine, with a focus on individualised clinical approaches, and give examples of sources of autologous cells with potential for clinical intervention.

show abstract

“…However, the fertilized embryos used to derive hESCs possess the potential to develop into human beings, and should be especially respected to maintain the fundamental social value of Bhuman dignity^ [5]. The use of hESCs in clinical studies raises ethical issues from a different standpoint compared with the use of other types of stem cell [6]. At the present time, policies concerning ethical issues related to hESCs vary greatly around the world [7].…”

Section: Introductionmentioning

confidence: 99%

Ethical Issues for Clinical Studies That use Human Embryonic Stem Cells: The 2014 Revisions to the Japanese Guidelines

Mizuno

2015

Stem Cell Rev and Rep

View full text Add to dashboard Cite

The use of human embryonic stem cells (hESCs) in clinical studies has been expanding in recent years. The application of hESCs in clinical studies raises ethical issues from a different standpoint compared with the use of other types of stem cells. In Japan, the Guidelines on the Derivation of Human Embryonic Stem Cells, and Guidelines on the Distribution and Utilization of Human Embryonic Stem Cells had been revised for clinical studies in 2014. In the revised guidelines, the method for protection of personal information was changed to offer the choice between unlinkable anonymization and linkable anonymization, to enable the use of information on diseases suffered by donors and the assurance of traceability for safety. Procedures for re-consent are generally prohibited out of consideration for donors' feelings. However, obtaining re-consent is permitted when consent for re-consent has been received in advance and approval has been given by an ethical review board, in which case the donors may be contacted. Incidental findings obtained from hESCs are not disclosed individually to donors, while the research results should be actively published for the common good. These guidelines have enabled the derivation, distribution, and use of hESCs for clinical studies.

show abstract

Do we Still Need Human Embryonic Stem Cells for Stem Cell-Based Therapies? Epistemic and Ethical Aspects

Cited by 23 publications

References 44 publications

Myt1l induced direct reprogramming of pericytes into cholinergic neurons

Myt1l induced direct reprogramming of pericytes into cholinergic neurons

Autologous stem cells for personalised medicine

Ethical Issues for Clinical Studies That use Human Embryonic Stem Cells: The 2014 Revisions to the Japanese Guidelines

Contact Info

Product

Resources

About